drugset
drugset / Trial / NCT02181088

A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5

NCT02181088 ↗

Phase 1 Completed 26 enrolled University of Oxford European Commission · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess two new malaria vaccines, ChAd63 RH5 and MVA RH5, at different doses and alone or in combination. The study will enable us to assess the safety of the vaccines and the extent of the immune response in healthy volunteers. We will do this by giving volunteers one or two vaccinations, doing blood tests and collecting information about any symptoms that occur after vaccination. This is the first trial to use these vaccines in humans.

Timeline

Start
2014-08
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ChAd63 RH5 Vaccine 5e+09 unknown Intramuscular
Subject ChAd63 RH5 Vaccine 5e+10 unknown Intramuscular
Subject MVA RH5 Vaccine 1e+08 unknown Intramuscular
Subject MVA RH5 Vaccine 2e+08 unknown Intramuscular

Indications

Plasmodium falciparum malaria